Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/18/2025

Cardiovascular Health in Pregnancy and Breastfeeding

Introduction to Cardiovascular Health

  • Cardiovascular health is crucial during pregnancy and breastfeeding, with guidelines provided by the American College of Cardiology and the European Heart Journal 1, 2, 3

Contraindications and Recommendations for Lipid-Lowering Medications

  • Statins should not be initiated during breastfeeding due to potential risks to the infant and lack of safety data, as recommended by the European Society of Cardiology 2
  • Women planning pregnancy should discontinue statins 1-2 months before conception, as recommended by the American College of Cardiology 4
  • Bile acid sequestrants are the only lipid-lowering medications considered safe for use during pregnancy, while statins and other systemically absorbed lipid-lowering drugs should be discontinued at least 3 months before planned conception and during pregnancy, according to the American College of Cardiology and American Heart Association guidelines 1, 5, 6, 7
  • Ezetimibe, bempedoic acid, and PCSK9 inhibitors should be discontinued when pregnancy is recognized due to insufficient or no available safety data, as stated by the American College of Cardiology and Diabetes Care 5, 7
  • Inclisiran and lomitapide are not recommended in pregnancy due to concerns for fetal harm, as stated by the American College of Cardiology 5

Special Considerations for High-Risk Patients

  • Women with Homozygous Familial Hypercholesterolemia (HoFH) or established atherosclerotic cardiovascular disease (ASCVD) may require special consideration, and consultation with a lipid specialist is strongly recommended, with lipoprotein apheresis possibly considered during pregnancy, according to the National Lipid Association and the American Heart Association 1
  • Statin continuation may be considered in rare cases for women with a history of ASCVD, HoFH, or severe heterozygous FH, in a shared decision-making process, according to Diabetes Care 7
  • Cardiovascular imaging (CT angiography or echocardiography) should be offered before planned pregnancy for women with HoFH or high-risk Severe Heterozygous FH (HeFH), according to the American Heart Association guidelines and the American College of Cardiology 1

Lifestyle Modifications and Monitoring

  • Heart-healthy diet and appropriate physical activity should be prioritized before, during, and after pregnancy, as recommended by the American College of Cardiology and the European Heart Journal 1, 2, 3
  • Regular monitoring of blood pressure and metabolic factors is essential for women with hyperlipidemia during pregnancy, although the specific guidelines are not provided 1
  • Lifestyle modifications, regular blood pressure control, and metabolic factor management should be implemented after delivery, as recommended by the European Heart Journal 2

Post-Pregnancy Care

  • Lipid-lowering medications may be resumed after completion of breastfeeding, and lifestyle modifications, blood pressure control, and metabolic factor management should be continued, as stated by the American College of Cardiology, although the specific citation is not provided, the general guideline is 1, 5, 2
  • Women of childbearing potential taking lipid-lowering medications should use effective contraception, as recommended by the American College of Cardiology 8, 1

Referral and Decision-Making

  • Referral to a lipid specialist is strongly recommended for high-risk patients, according to the American College of Cardiology 5
  • The decision to continue lipid-lowering therapy during pregnancy should be based on the woman's cardiovascular risk profile, with continuation generally limited to those with HoFH or established ASCVD, as recommended by the American College of Cardiology and the Nature Reviews Cardiology 5, 1

REFERENCES